用户名:  密码:   
网站首页即时通讯活动公告最新消息科技前沿学人动向两岸三地人在海外历届活动关于我们联系我们申请加入
栏目导航 — 美国华裔教授专家网活动公告学术论坛
关键字  范围   
 
SABPA:Immunotherapy, New Frontier of Disease Treatment(3/14)
SABPA:Immunotherapy, New Frontier of Disease Treatment(3/14)
2015/3/3 2:53:42 | 浏览:1314 | 评论:0

SABPA:Immunotherapy, New Frontier of Disease Treatment(3/14)

SABPA Science & Technology Forum XIII:Immunotherapy, the New Frontier of Disease Treatment

Date:14th Mar, 2015

SABPA:Immunotherapy, New Frontier of Disease Treatment(3/14)


Immunotherapy, the New Frontier of Disease Treatment

Date: March 14, 2015(Saturday)8:30am To 1:00pm(Breakfast and lunch will be provided)

Location: Institute of Americas, UCSD

(directions available at http://www.sabpa.org/web/news_details.php?ID=449

Registration: https://www.123signup.com/register?id=yppvf

$20 for online registration, $10 for students and post-docs. $40 for on-site registration, Online registration ends March 11, 2015

Immunotherapy including allergy, diabetes and cancer immunotherapy has been studied for decades, but only recently has it received much attention, especially in oncology area of research. It was the central topic at recent 2014 AACR(American Association for Cancer Research)and ASCO(American Society of Clinical Oncology)annual meetings. With recent FDA approval of immunotherapy agents from Merck and Bristol-Myers for the treatment of cancer, and with much more under development and clinical trials globally, immunotherapy could be the game-changing treatment with its potential to cure certain types of cancer. Many pharmaceutical companies have renewed their strong interests and invested greatly in immunotherapy for multiple disease areas either internally or through external collaborations.

This year’s SABPA Science & Technology Forum XIII will focus on current frontiers in immunotherapy. It will bring academic and industry leaders in the immunotherapy field from San Diego and its neighboring area as well as investigators from immunotherapy centers in China to address opportunities and challenges of immunotherapy in many disease areas, particularly in cancer.

speakers

Matthias von Herrath, M.D.

Director of the Center for Type 1 Diabetes Research, La Jolla Institute of Allergy and Immunology

Jonathan Benjamin, M.D.

Medical Director, Amgen

Michael Cooke, Ph.D.

Director of Immunology, Genomics Institute of the Novartis Research Foundation

Jamey Skillings, M.D.

CMO, Tocagen

Greg Daniels, M.D

Medical Oncologist, UCSD Thornton Hospital and UCSD Medical Center

Jon Berglin

CEO, Theragene

Lewis R. Vann, Ph.D.

Senior Manager, Business Development, the Jackson Laboratory

Tags:
相关栏目:『学术论坛
Experience & Expression:Reading Chinese Literature Across Genres 2023-01-31 [80]
Doing Hong Kong History:New Generation, New Direction(2/9) 2023-01-31 [99]
UCLA CCS | Trafficking Data:How China is Winning the Battle for Digital Sovereignty 2023-01-30 [130]
UCLA| Iridescent Corners:Sinophone Flash Fiction in Singapore 2023-01-30 [115]
UCLA CCS:Russian Expeditions to Central Asia & the Discovery of the Desert Ruins of Khara-Khoto 2023-01-20 [177]
合肥工大2023国际青年学者论坛邀请您:携手并进 共创一流! 2023-01-19 [181]
中国传媒大学首届“金核桃”国际青年学者论坛 2022-12-16 [345]
加州州立大学北岭分校:Speech Perception & Enhancement in Noise 2022-12-01 [504]
UCLA CCS: Teach-in Webinar (12/2/2022) 2022-11-29 [457]
UCLA CCS:Chip War:The Fight for the World's Most Critical Technology 2022-11-21 [489]
相关栏目更多文章
最新图文:
:《2019全球肿瘤趋势报告》 :阿尔茨海默病预防与干预核心讯息图解 :引力波天文台或有助搜寻暗物质粒子 :Sail Through the Mist - SoCal Innovation Forum 2019(10/5) 游天龙:《唐人街》是如何炼成的:UCLA社会学教授周敏的学术之路 :“为什么海外华人那么爱国,但是让他回国却不愿意?...“ :学术出版巨头Elsevier 彻查433名审稿人“强迫引用”黑幕 :中国336个国家重点实验室布局
更多最新图文
更多《即时通讯》>>
 
打印本文章
 
您的名字:
电子邮件:
留言内容:
注意: 留言内容不要超过4000字,否则会被截断。
未 审 核:  是
  
关于我们联系我们申请加入后台管理设为主页加入收藏
美国华裔教授专家网版权所有,谢绝拷贝。如欲选登或发表,请与美国华裔教授专家网联系。
Copyright © 2023 ScholarsUpdate.com. All Rights Reserved.